ObsEva Funding: How Much Did They Raise & Key Investors

How Much Did ObsEva Raise?
Funding & Key Investors

ObsEva, a biopharmaceutical firm focused on women's reproductive health, has secured $96.8M in total capital, with a recent major strategic investment of $96.8M. This significant financing underscores the company's progress in developing novel therapies for conditions such as uterine fibroids, endometriosis, and preterm labor. The enterprise-level funding indicates a pivotal stage for the company's growth and market expansion initiatives.

What is ObsEva?

ObsEva

Manufacturing

Pharmaceuticals

Business Services

ObsEva is a biopharmaceutical company dedicated to advancing women's reproductive health and pregnancy through the development and commercialization of innovative therapies. The company has strategically built a late-stage clinical pipeline targeting key areas including uterine fibroids, endometriosis, and preterm labor. Listed on both the Nasdaq Global Select Market (OBSV) and the SIX Swiss Exchange (OBSN), ObsEva leverages in-licensing and disciplined drug development to bring its novel treatments to market.

How much funding has ObsEva raised?

ObsEva has raised a total of $96.8M across 1 funding round:

2017

Stock Offering

$96.8M

Stock Issuance/Offering (2017): $96.8M, investors not publicly disclosed

What's next for ObsEva?

With the recent major strategic investment, ObsEva is poised to accelerate its development programs and potentially expand its commercial reach. The substantial enterprise-level funding suggests a strategic focus on advancing its late-stage pipeline through clinical trials and regulatory approvals. This capital infusion is expected to bolster ObsEva's efforts in addressing unmet needs in women's health, potentially leading to significant market impact and further value creation for its stakeholders.

See full ObsEva company page

See More Financial Insights